LAFAYETTE HILL, PA, September, 2006

As the demand for safety, efficacy, and affordability becomes critical to large pharmaceutical and start-up companies with product development and entry into market, SommaTech, LLC is born. SommaTech, a new affiliate of IPS – a leading, fully-integrated engineering firm for the pharmaceutical and biopharma sector – helps clients achieve their FDA regulated product goals for a fast submission and seamless approval, as well as assuring a cost effective product and secure supply chain...

Sommatech, A Pharmaceutical Technology Consulting Firm, Formed

– Providing Value-Added Solutions That Speed Pharma Products To Market-

As the demand for safety, efficacy, and affordability becomes critical to large pharmaceutical and start-up companies with product development and entry into market, SommaTech, LLC is born. SommaTech, a new affiliate of IPS – a leading, fully-integrated engineering firm for the pharmaceutical and biopharma sector – helps clients achieve their FDA regulated product goals for a fast submission and seamless approval, as well as assuring a cost effective product and secure supply chain. Primary industries served by SommaTech’s team of highly-technical, flexible specialists include pharmaceutical, biotechnology, medical devices, combination products, diagnostics, food supplements and natural products. Key service areas are drug development, operations and compliance. In addition, SommaTech provides a full range of business support for its clients including due diligence for products, quality risk analysis for products and processes, methods development, and life cycle management, to name a few.

“After 30 years of experience in the pharmaceutical industry, specifically in the areas of production troubleshooting, dosage form development, manufacturing scale up, technology transfer and project management, it was clear that the industry demands a consulting firm such as SommaTech,” says Russ Somma, Ph.D., President, SommaTech, LLC. “What makes SommaTech unique is our ability to deliver affordable, innovative solutions that impact the process of drug product development at an early stage, resulting in rapid product entry into the market. SommaTech provides an unequaled level of more than 100 years of experience in product development and manufacturing covering a wide range of pharmaceutical products and processes. There is no substitute for deep industry experience when combined with direction on leveraging technological innovation, along with the ability to draw on the breadth of services available from the industry leading IPS organization – this is a real advantage to clients.” SommaTech’s experience is evident in every aspect of its team’s personalized services to every client, and their commitment to continuous improvement, technical excellence and credibility earned by a success based industry history. “We are not only consult to develop solutions, we implement, track and close. We have been delivering our services for over a year and are proud to have been effective and successful,” adds Somma.

For more information about SommaTech contact Kim Goodman at 888.366.7660 ext. 326 or This email address is being protected from spambots. You need JavaScript enabled to view it..

About Russell Somma, Ph.D. – Dr. Russ Somma has been involved in production support, scale-up, pilot plant as well as early and full development activities of pharmaceutical products, which include novel as well as traditional dosage forms during his 29 year tenure with Novartis. He has provided support for 21 NDAs in the chemistry, manufacturing and control area from submission through the pre approval inspection phase. As president of SommaTech, an affiliate company of IPS, his focus is on pharmaceutical technology and helping clients achieve their FDA regulated product goals for a fast submission, seamless approval as well as assuring a cost effective product and a secure supply chain. He is the past chairman of ISPE’s SUPAC Equipment Guidance Steering Committee. He currently chairs the ISPE-Professional Certification Commission. Dr. Somma has been a welcomed keynote speaker and presenter at many pharmaceutical industry association meetings and has written and co-authored several technical papers and studies. Dr. Somma earned as Ph.D. in Pharmaceutical Technology under N.G. Lordi at Rutgers University College of Pharmacy, a BS degree in Pharmacy and a MS degree also from Rutgers University.